LDS/Medical Tests/Testosterone, Total

Testosterone, Total

Testosterone is the major androgen (sex hormone) in males. Its production is controlled by luteinizing hormone (LH), which is released from the anterior pituitary gland.  It stimulates testosterone secretion from the Leydig cells in the testes.  Testosterone stimulates adult maturation of external genitalia and secondary sex characteristics such as the growth of beard and body hair. In addition, testosterone has anabolic (stimulates the growth of bone and muscle) effects leading to increased linear growth, nitrogen retention, and muscular development. Clinical evaluation of serum testosterone, along with serum LH, assists in evaluation of hypogonadal males. Major causes of lowered testosterone in males include hypogonadotropic hypogonadism, testicular failure, hyperprolactinemia, hypopituitarism, some types of liver and kidney diseases, and critical illness.  This may lead to signs and symptoms including loss of libido, loss of reproductive function and changes in secondary sexual characteristics.

Testosterone levels are much lower in females compared to males.  Its main function in women is to serve as a precursor for estrogen.  The major sources of testosterone in premenopausal females are the ovaries with lesser amounts from the adrenal glands and from peripheral conversion of androstenedione. In females, increased serum testosterone levels may be indicative of polycystic ovary syndrome and adrenal hyperplasia;  however, mild to moderate elevations in women are often of unknown cause. The clinical manifestations of excess testosterone include infertility, hirsutism (excessive hairiness), amenorrhea (lack of menstruation), mood swings with occasional aggressiveness and obesity.

Testosterone strongly binds to plasma proteins. It is predominantly bound to a specific sex hormone-binding globulin (SHBG, aka testosterone-estradiol-binding globulin, TeBG) (60%) and a lesser amount is bound to albumin (38%).  It had been thought that only free testosterone is bioavailable, but more recently it has been demonstrated that testosterone is only weakly bound to albumin and can dissociate in the peripheral capillary bed and become available.  Therefore, current data suggests all no-TeBG bound testosterone is bioavailable.  The total testosterone level measures both bound and free testosterone in the serum. Free or bioavailable testosterone may be calculated or measured. Free or bioavailable testosterone is also used to monitor testosterone levels in postmenopausal women treated with testosterone.

  • Evaluation of LH secretion and Leydig cell function
  • Evaluation of gonadal and adrenal function
  • Diagnosis of hypogonadism in males and hirsutism and virilization in females
  • Infertility (men and women)
  • Testicular tumors
  • Hormone (testosterone) therapy monitoring in postmenopausal women
  • Evaluation of delayed puberty or precocious puberty in boys
  • Monitoring anti-androgen therapy (e.g., prostate cancer therapy)
  • Evaluation of infants with ambiguous genetalia or virilization
  • Diagnosis of androgen secreting tumors

Increased in:

  • Idiopathic sexual precocity (in boys, levels may be in adult range)
  • Polycystic ovary syndrome (in females)
  • Adrenal hyperplasia
  • Adrenocortical tumors
  • Trophoblastic disease during pregnancy
  • Idiopathic hirsutism
  • Virilizing ovarian tumors
  • Arrhenoblastoma
  • Virilizing luteoma
  • Liver cirrhosis (through increased SHBG)
  • Hyperthyroidism
  • Some drugs such as anticonvulsants, barbiturates, estrogens, oral contraceptives (through increased SHBG)
  • Testicular feminization
  • Extragonadal tumors producing gonadotropin in men
  • Hilar cell tumor

Decreased in:

  • Hypogonadism, primary and secondary
  • Orchidectomy
  • Klinefelter syndrome
  • Liver insufficiency
  • Some drugs: digoxin, spironolactone, acarbose
  • Down syndrome
  • Uremia
  • Myotonic dystrophy
  • Cryptorchidism
  • Delayed puberty in boys

Note: the diagnosis of male hypogonadism is based on clinical symptoms and signs plus laboratory confirmation of low morning total serum testosterone levels on two different occasions. Levels below 3.0 ng/mL should be treated. Free testosterone should be measured in symptomatic patients with normal total testosterone levels. Obtain serum luteinizing hormone and FSH levels to distinguish between primary (hypergonadotropic) and secondary (hypogonadotropic) hypogonadism. Hypogonadism associated with aging (andropause) may present a mixed picture, with low testosterone levels and low to low-normal gonadotropin levels.

Units: ng/dL / nmol/L

Age Group Sex ng/dL nmol/L
Newborn Male 75–400 2.6–13.9
Female 20–64 0.69–2.22
1–5 mo Male 1–177 0.03–6.14
Female 1–5 0.03–0.17
6–11 mo Male 2–7 0.07–0.24
Female 2–5 0.07–0.17
1–5 yr Male 2–25 0.07–0.87
Female 2–10 0.07–0.35
6–9 yr Male 3–30 0.10–1.04
Female 2–20 0.07–0.69
Adult Male 280–1100 9.72–38.17
Female 15–70 0.52–2.43
Pregnancy 3–4 × adult level
Postmenopausal 8–35 0.28–1.22
Chemiluminescent enzymeimmunoassay, Liquid chromatography and Mass spectrometry (LC/MS).

Serum Red top preferred, Serum gel (SST) acceptable. 

Stability

  • Ambient: 5-7 days
  • Refrigerated: 7-14 days
  • Frozen: 6 months
Luteinizing hormone (LH), Follicle-stimulating hormone (FSH), Estrogen, Testosterone free, Sex hormone-binding globulin (SHBG), Aldosterone, Vitamin D-25OH, Cortisol, Dihydroepiandrosterone, Dihydrotestosterone, Inhibin A, Calcium, Complete Semen Analysis, Liver function studies.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Ann Clin Biochem. 2006 Jan;43(Pt 1):3-12. [PMID: 16390603]
  • Front Horm Res. 2009;37:21-31. [PMID: 19011286]
  • Methods Mol Biol. 2006;324:197-211. [PMID: 16761380]
  • Ann Clin Biochem. 1995 Jul;32 ( Pt 4):345-57. [PMID: 7486793]
  • Ann Clin Biochem. 2006;43(Pt 1):3. [PMID: 16390603]
  • Best Pract Res Clin Endocrinol Metab. 2006;20:177. [PMID: 16772150]
  • Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757